Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of an 11-valent recombinant HPV vaccine in Chinese women aged 18-45 years
CTR20221258Phase 3Active
- Sponsor
- National Vaccine & Serum Institute
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of 11-valent recombinant human papilloma virus vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), anogenital warts, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), sponsored by National Vaccine & Serum Institute. Started Jun 2022; status: active.
02
Drugs
11-valent recombinant human papilloma virus vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)anogenital wartsvulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)
Beyond the preview
Go deeper on CTR20221258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221258.